RTP Mobile Logo
Oncology Nursing Update, Lung Cancer Edition, Issue 1, 2017 (Video Program)
Released September 2017

Highlights from video interviews with clinical investigators Drs Lecia V Sequist and David R Spigel and nurses Ms Kelly EH Goodwin and Ms Mollie Reed on the latest research developments in the management of lung cancer.

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Traditionally, chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes for patients with lung cancer. However, the advent of biologic agents and immunotherapies has led to recent improvements in disease-free and overall survival in select patient populations. Importantly, published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with lung cancer, this issue of Oncology Nursing Update uses one-on-one interviews with medical oncologists and nurses who are experts in the field. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with lung cancer.

    PURPOSE STATEMENT
    To present the most current recent research developments and to provide the perspectives of nurse practitioners and clinical investigators on the diagnosis and treatment of lung cancer.

    LEARNING OBJECTIVES

    • Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of lung cancer, including chemotherapy regimens, targeted biologic treatments and immunotherapeutic approaches.
    • Communicate the clinical relevance of tumor histology and commonly identified genetic abnormalities to patients with non-small cell lung cancer.
    • Educate patients receiving EGFR and ALK inhibitors about potential side effects, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.
    • Develop an understanding of the mechanism of action, efficacy and safety/toxicities of anti-PD-1 checkpoint inhibitors to enable their appropriate integration into routine clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. 

    CREDIT DESIGNATION STATEMENT
    This educational activity for 2.25 contact hours is provided by Research To Practice during the period of August 2017 through August 2018.

    This activity is awarded 2.25 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

    To review certification qualifications please visit ResearchToPractice.com/ONULung117/Video/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video and complete the Post-test and Educational Assessment and Credit Form located at ResearchToPractice.com/ONULung117/Video/CNE. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 80% or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kelly EH Goodwin, MSN, RN, ANP-BC
    Center for Thoracic Cancers
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    No relevant conflicts of interest to disclose. 

    Mollie Reed, MSN, RN, ACNP-BC
    Nurse Practitioner
    Tennessee Oncology
    Sarah Cannon Research Institute
    Nashville, Tennessee 

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Taiho Oncology Inc; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Taiho Oncology Inc. 

    Lecia V Sequist, MD, MPH
    Associate Professor of Medicine
    Harvard Medical School
    Center for Thoracic Cancers
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 

    Advisory Committee: Ariad Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Genentech BioOncology, Merrimack Pharmaceuticals Inc, Novartis. 

    David R Spigel, MD
    Program Director, Lung Cancer Research
    Sarah Cannon Research Institute
    Nashville, Tennessee 

    No relevant conflicts of interest to disclose. 

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology and Lilly. 

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: September 2017
    Expiration date: September 2018

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Management of EGFR mutation-positive non-small cell lung cancer (NSCLC)

ALK-rearranged lung cancer and its treatment

Role of immune checkpoint inhibitors in NSCLC

Optimal use of chemotherapy for metastatic NSCLC

Select Publications